MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 526638 | Name: Traxoprodil Mesylate
Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Traxoprodil Mesylate is a selective NMDA receptor antagonist that preferentially inhibits NR2B subunit-containing receptors, reducing excitotoxicity associated with neurological disorders. It has been investigated for its potential in treating stroke, neuropathic pain, and depression by modulating glutamatergic signaling. The mesylate salt form enhances its solubility and stability for research applications.

Chemical Structure

Traxoprodil Mesylate
Traxoprodil Mesylate
CAS#188591-67-5 (mesylate)

Theoretical Analysis

MedKoo Cat#: 526638

Name: Traxoprodil Mesylate

CAS#: 188591-67-5 (mesylate)

Chemical Formula: C21H29NO6S

Exact Mass: 0.0000

Molecular Weight: 423.52

Elemental Analysis: C, 59.56; H, 6.90; N, 3.31; O, 22.67; S, 7.57

Price and Availability

Size Price Availability Quantity
5mg USD 280.00 2 Weeks
25mg USD 810.00 2 Weeks
Bulk Inquiry
Buy Now
Add to Cart
Related CAS #
134234-12-1 (free base) 188591-67-5 (mesylate)
Synonym
Traxoprodil Mesylate
IUPAC/Chemical Name
1-((1S,2S)-1-hydroxy-1-(4-hydroxyphenyl)propan-2-yl)-4-phenylpiperidin-4-ol methanesulfonate
InChi Key
OZBWUANKVIMZIA-WRRDZZDISA-N
InChi Code
InChI=1S/C20H25NO3.CH4O3S/c1-15(19(23)16-7-9-18(22)10-8-16)21-13-11-20(24,12-14-21)17-5-3-2-4-6-17;1-5(2,3)4/h2-10,15,19,22-24H,11-14H2,1H3;1H3,(H,2,3,4)/t15-,19+;/m0./s1
SMILES Code
OC1=CC=C(C=C1)[C@@H]([C@@H](N2CCC(C3=CC=CC=C3)(CC2)O)C)O.CS(=O)(O)=O
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 423.52 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: DePoy LM, Zimmermann KS, Marvar PJ, Gourley SL. Induction and Blockade of Adolescent Cocaine-Induced Habits. Biol Psychiatry. 2017 Apr 1;81(7):595-605. doi: 10.1016/j.biopsych.2016.09.023. Epub 2016 Oct 6. PubMed PMID: 27871669; PubMed Central PMCID: PMC5359769. 2: Stasiuk W, Serefko A, Szopa A, Wyska E, Świąder K, Wlaź P, Poleszak E. Traxoprodil augments the antidepressant-like activity of agomelatine but not of mianserin or tianeptine in the forced swim test in mice. Pharmacol Rep. 2016 Oct;68(5):960-3. doi: 10.1016/j.pharep.2016.04.013. Epub 2016 May 4. PubMed PMID: 27371898. 3: Higgins GA, Silenieks LB, MacMillan C, Sevo J, Zeeb FD, Thevarkunnel S. Enhanced attention and impulsive action following NMDA receptor GluN2B-selective antagonist pretreatment. Behav Brain Res. 2016 Sep 15;311:1-14. doi: 10.1016/j.bbr.2016.05.025. Epub 2016 May 11. PubMed PMID: 27180168. 4: Nagy D, Stoiljkovic M, Menniti FS, Hajós M. Differential Effects of an NR2B NAM and Ketamine on Synaptic Potentiation and Gamma Synchrony: Relevance to Rapid-Onset Antidepressant Efficacy. Neuropsychopharmacology. 2016 May;41(6):1486-94. doi: 10.1038/npp.2015.298. Epub 2015 Sep 25. PubMed PMID: 26404843; PubMed Central PMCID: PMC4832008. 5: Kumar G, Olley J, Steckler T, Talpos J. Dissociable effects of NR2A and NR2B NMDA receptor antagonism on cognitive flexibility but not pattern separation. Psychopharmacology (Berl). 2015 Nov;232(21-22):3991-4003. doi: 10.1007/s00213-015-4008-9. Epub 2015 Jul 18. PubMed PMID: 26184010. 6: Weed MR, Bookbinder M, Polino J, Keavy D, Cardinal RN, Simmermacher-Mayer J, Cometa FN, King D, Thangathirupathy S, Macor JE, Bristow LJ. Negative Allosteric Modulators Selective for The NR2B Subtype of The NMDA Receptor Impair Cognition in Multiple Domains. Neuropsychopharmacology. 2016 Jan;41(2):568-77. doi: 10.1038/npp.2015.184. Epub 2015 Jun 24. PubMed PMID: 26105137; PubMed Central PMCID: PMC5130132. 7: Graef JD, Newberry K, Newton A, Pieschl R, Shields E, Luan FN, Simmermacher J, Luchetti D, Schaeffer E, Li YW, Kiss L, Bristow LJ. Effect of acute NR2B antagonist treatment on long-term potentiation in the rat hippocampus. Brain Res. 2015 Jun 3;1609:31-9. doi: 10.1016/j.brainres.2015.03.019. Epub 2015 Mar 19. PubMed PMID: 25796435. 8: Kong M, Ba M, Liu C, Zhang Y, Zhang H, Qiu H. NR2B antagonist CP-101,606 inhibits NR2B phosphorylation at tyrosine-1472 and its interactions with Fyn in levodopa-induced dyskinesia rat model. Behav Brain Res. 2015 Apr 1;282:46-53. doi: 10.1016/j.bbr.2014.12.059. Epub 2015 Jan 8. PubMed PMID: 25576965. 9: Liddie S, Itzhak Y. Variations in the stimulus salience of cocaine reward influences drug-associated contextual memory. Addict Biol. 2016 Mar;21(2):242-54. doi: 10.1111/adb.12191. Epub 2014 Oct 28. PubMed PMID: 25351485; PubMed Central PMCID: PMC4412748. 10: Booth R, Kim H. Permeability analysis of neuroactive drugs through a dynamic microfluidic in vitro blood-brain barrier model. Ann Biomed Eng. 2014 Dec;42(12):2379-91. doi: 10.1007/s10439-014-1086-5. Epub 2014 Aug 13. PubMed PMID: 25118670. 11: Gomes GM, Dalmolin GD, Bär J, Karpova A, Mello CF, Kreutz MR, Rubin MA. Inhibition of the polyamine system counteracts β-amyloid peptide-induced memory impairment in mice: involvement of extrasynaptic NMDA receptors. PLoS One. 2014 Jun 12;9(6):e99184. doi: 10.1371/journal.pone.0099184. eCollection 2014. PubMed PMID: 24921942; PubMed Central PMCID: PMC4055672. 12: Hansen KB, Ogden KK, Yuan H, Traynelis SF. Distinct functional and pharmacological properties of Triheteromeric GluN1/GluN2A/GluN2B NMDA receptors. Neuron. 2014 Mar 5;81(5):1084-1096. doi: 10.1016/j.neuron.2014.01.035. PubMed PMID: 24607230; PubMed Central PMCID: PMC3957490. 13: Naspolini AP, Cocco AR, Villa Martignoni F, Oliveira MS, Furian AF, Rambo LM, Rubin MA, Barron S, Mello CF. Traxoprodil decreases pentylenetetrazol-induced seizures. Epilepsy Res. 2012 Jun;100(1-2):12-9. doi: 10.1016/j.eplepsyres.2012.01.002. Epub 2012 Jan 24. PubMed PMID: 22281061. 14: Lewis B, Wellmann KA, Kehrberg AM, Carter ML, Baldwin T, Cohen M, Barron S. Behavioral deficits and cellular damage following developmental ethanol exposure in rats are attenuated by CP-101,606, an NMDAR antagonist with unique NR2B specificity. Pharmacol Biochem Behav. 2012 Jan;100(3):545-53. doi: 10.1016/j.pbb.2011.10.013. Epub 2011 Oct 20. PubMed PMID: 22037411. 15: Swartjes M, Morariu A, Niesters M, Aarts L, Dahan A. Nonselective and NR2B-selective N-methyl-D-aspartic acid receptor antagonists produce antinociception and long-term relief of allodynia in acute and neuropathic pain. Anesthesiology. 2011 Jul;115(1):165-74. doi: 10.1097/ALN.0b013e31821bdb9b. PubMed PMID: 21606828. 16: Rauner C, Köhr G. Triheteromeric NR1/NR2A/NR2B receptors constitute the major N-methyl-D-aspartate receptor population in adult hippocampal synapses. J Biol Chem. 2011 Mar 4;286(9):7558-66. doi: 10.1074/jbc.M110.182600. Epub 2010 Dec 29. PubMed PMID: 21190942; PubMed Central PMCID: PMC3045010. 17: Quintana A, Melon C, Kerkerian-Le Goff L, Salin P, Savasta M, Sgambato-Faure V. Forelimb dyskinesia mediated by high-frequency stimulation of the subthalamic nucleus is linked to rapid activation of the NR2B subunit of N-methyl-D-aspartate receptors. Eur J Neurosci. 2010 Aug;32(3):423-34. doi: 10.1111/j.1460-9568.2010.07290.x. Epub 2010 Jul 28. PubMed PMID: 20673310. 18: Tallaksen-Greene SJ, Janiszewska A, Benton K, Ruprecht L, Albin RL. Lack of efficacy of NMDA receptor-NR2B selective antagonists in the R6/2 model of Huntington disease. Exp Neurol. 2010 Oct;225(2):402-7. doi: 10.1016/j.expneurol.2010.07.015. Epub 2010 Jul 24. PubMed PMID: 20659453; PubMed Central PMCID: PMC2939157. 19: Hashimoto K. Comments on "An innovative design to establish proof of concept of the antidepressant effects of the NR2B subunit selective N-methyl-D-aspartate antagonist, CP-101,606 in patients with treatment-refractory major depressive disorder". J Clin Psychopharmacol. 2009 Aug;29(4):411-2; author reply 412. doi: 10.1097/JCP.0b013e3181ace848. PubMed PMID: 19593196. 20: Preskorn SH, Baker B, Kolluri S, Menniti FS, Krams M, Landen JW. An innovative design to establish proof of concept of the antidepressant effects of the NR2B subunit selective N-methyl-D-aspartate antagonist, CP-101,606, in patients with treatment-refractory major depressive disorder. J Clin Psychopharmacol. 2008 Dec;28(6):631-7. doi: 10.1097/JCP.0b013e31818a6cea. PubMed PMID: 19011431.